Regulation of Trabecular Meshwork Cell Contraction and Intraocular Pressure by miR-200c

Coralia Luna¹, Guorong Li¹, Jianyong Huang², Jianming Qiu¹, Jing Wu¹, Fan Yuan², David L. Epstein¹, Pedro Gonzalez¹*

¹ Department of Ophthalmology, Duke University, Durham, North Carolina, United States of America, ² Department of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America

Abstract

Lowering intraocular pressure (IOP) delays or prevents the loss of vision in primary open-angle glaucoma (POAG) patients with high IOP and in those with normal tension glaucoma showing progression. Abundant evidence demonstrates that inhibition of contractile machinery of the trabecular meshwork cells is an effective method to lower IOP. However, the mechanisms involved in the regulation of trabecular contraction are not well understood. Although microRNAs have been shown to play important roles in the regulation of multiple cellular functions, little is known about their potential involvement in the regulation of IOP. Here, we showed that miR-200c is a direct posttranscriptional inhibitor of genes relevant to the physiologic regulation of TM cell contraction including the validated targets Zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2), and formin homology 2 domain containing 1 (FHOD1), as well as three novel targets: lysophosphatidic acid receptor 1 (LPAR1/EDG2), endothelin A receptor (ETAR), and RhoA kinase (ROHA). Consistently, transfection of TM cells with miR-200c resulted in strong inhibition of contraction in collagen populated gels as well as decreased cell traction forces exerted by individual TM cells. Finally, delivery of miR-200c to the anterior chamber of living rat eyes resulted in a significant decrease in IOP, while inhibition of miR-200c using an adenoviral vector expressing a molecular sponge led to a significant increase in IOP. These results demonstrate for the first time the ability of a miRNA to regulate trabecular contraction and modulate IOP in vivo, making miR-200c a worthy candidate for exploring ways to alter trabecular contractility with therapeutic purposes in glaucoma.
Table 1. Primers used for Q-PCR amplification.

| Gene Symbol | FORWARD 5'-3' | REVERSE 5'-3' |
|-------------|---------------|---------------|
| ETAR        | TATCTGGCCATCCTGTGAAG | TTCTCAAGTCGCACTTCTT |
| ZEB2        | TTCTGGGCTGACACCTATC | TGTGCTCATAAGGACATTC |
| FHOD1       | GAGGACGACACACACAAATCG | TCACGTACTGCACAGAAGG |
| LPAR1       | ATCTTGATCCCCATCTCATCCCTT | ACTGACCAAACACACAA |
| ZEB1        | GGAGGGAGGAAGAAGTG | GCAGGTTACCTGCTG |
| GAPDH       | TCGACAGTCGAGCGCATCTTCTT | ACCAAACCTGTAAGCTGACCTT |

Gene names: ETAR, endothelin receptor A; ZEB2, Zinc finger E-box-binding homeobox 2; FHOD1, formin homology 2 domain containing 1; LPAR1, Lysophosphatidic acid receptor 1; ZEB1, Zinc finger E-box-binding homeobox 1; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.

doi:10.1371/journal.pone.0051688.t002

Table 2. Quantitative -PCR (Q-PCR) and Affymetrix arrays values for some targets and predicted targets of miR-200c.

| Gene symbol | ETAR | ZEB2 | FHOD1 | ZEB1 | LPAR1 |
|-------------|------|------|-------|------|-------|
| HTM36       | fold | 1.68958 | 6.9163 | 2.1785 | 2.45661 | 1.22264 |
| Q-PCR       | p-value | 0.00339 | 0.000162 | 0.000131 | 8.81E-05 | 0.027155 |
| HTM88       | fold | 1.5728 | 1.84463 | 1.12124 | 1.54043 | 1.59475 |
| Q-PCR       | p-value | 0.024349 | 0.012577 | 0.175064 | 0.011216 | 0.032013 |
| HTM23       | fold | 2.92432 | 4.90983 | 2.28431 | 3.461666 | 2.31909 |
| Arrays      | p-value | 0.003594 | 0.001477 | 0.005014 | 5.37E-05 | 0.000243 |

doi:10.1371/journal.pone.0051688.t001

Our previous studies have shown that miR-200c is highly expressed in TM cells [44]. A preliminary study on miRNAs induced by oxidative stress in HTM cells showed miR-200c as a highly up-regulated miRNA, and gene expression profile was analyzed after over-expressing miR-200c in HTM cells (data not published). Some genes that significantly change expressions were selected for further analysis because they were predicted targets of miR-200c and affect cell contraction. To gain insight on the role of miR-200c on contractility of the outflow pathway we investigate and identified novel target genes of miR-200c involved in the regulation of the contractile responses in TM cells, analyzed the effects of miR-200c on contraction forces exerted by TM cells, and evaluated the effects of changes in mim-200c activity on IOP in vivo.

Materials and Methods

Ethics Statement

The use of animals for this study was conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Duke University Institutional Animal Care & Use Committee (IACUC) (http://vetmed.duhs.duke.edu/IACUC.html) specifically approved this study. The Duke University School of Medicine Institutional Review Board (http://irb.duhs.duke.edu/) provided written informed consent for the original human work that produced the tissue samples.

Cell Culture Conditions

Human trabecular meshwork (HTM) primary cell cultures were generated from cadaver eyes, with no history of eye disease, as previously reported [45]. All procedures involving human tissue were conducted in accordance with The tenets of the Declaration of Helsinki. Human embryonic kidney 293A (HEK293A) cell line was purchased from Invitrogen (Carlsbad, CA). Cell cultures were maintained at 37°C in 5% CO2 in media (low glucose Dulbecco’s Modified Eagle Medium with L-glutamine, 110 mg/ml sodium pyruvate, 10% fetal bovine serum, 100 µM non-essential amino acids, 100 units/ml penicillin, 100 µg/ml streptomycin sulfate). All the reagents were obtained from Invitrogen (Carlsbad, CA).

RNA isolation and Quantitative PCR (Q-PCR)

Total RNA was isolated using RNeasy kit (Qiagen Inc, Valencia, CA) according to the manufacturer’s instructions. RNA yields were measured using Ribogreen fluorescent dye (Invitrogen). First strand cDNA was synthesized from total RNA (600 ng) by reverse transcription using oligo(dT) and Superscript II reverse transcriptase (Invitrogen) according to manufacturer’s instructions. Q-PCR reactions were performed in 20 µl mixture containing 1 µl of the cDNA preparation, 1X IQ SYBR Green Supermix (BioRad, Hercules, CA), using the following PCR parameters: 95°C for 5 minutes followed by 50 cycles of 95°C for 15 seconds, 65°C for 15 seconds and 72°C for 15 seconds. GAPDH was used as internal standard of mRNA expression. The absence of nonspecific products was confirmed by both the analysis of the melt curves and by electrophoresis in 3% Super acrylAgarose gels. The primers used for Q-PCR amplification were design using Primer 3 [46] and are shown in Table 1.

Transfections

HTM primary cells were transfected, at 50 to 70% confluency next day after plating, with hsa-miR-200c mimic, control mimic (scramble) or control fluorescent mimic DY547 (40 pmol) (Thermo Scientific, Chicago, IL) using lipofectamine 2000 (Invitrogen), following manufacturer’s instructions. Co-transfections in 293A cells with luciferase 3'UTR constructs (300 ng) and miR-200c mimic or scramble (20 pmol) was accomplished using Effectene (Qiagen).

Gene Microarray Analysis

Gene array analysis was conducted with either miR-200c mimic or mimc control on a HTM primary cell line (HTM23). Total RNA was extracted three days post-transfection using RNeasy kit (Qiagen), amplified (1 round amplification) using One cycle target labeling and control reagents (Affymetrix, Santa Clara, CA) and hybridized to Human Genome U133A2 Arrays (Affymetrix) at Duke University Microarray facility. Raw data was normalized and analyzed using GeneSpring GX10 (Silicon Genetics). Inten-
sity-dependent normalization was performed per spot and per chip (LOWESS). ANOVA test was performed (p-values ≤ 0.05) for genes differentially expressed using the Benjamin and Hochberg False Discovery Rate correction test.

**Analysis of miR-200c Interaction with 3’ UTRs**

The entire 3’ UTR from lisophosphatidic acid receptor 1 (LPAR1) and partial 3’ UTR from endothelin receptor A (ETAR) and RhoA, including miR-200c complementary sites, were amplified from human sequences using the following primers: LPAR1-F-gtggtttagaacggaaactg and LPAR1-R-aggtggttacttctgggttg; ETAR-F-tctagactgtctctgtggaa and ETAR-R-gccttgcaattcaagcaact; RhoA-F cgcttttgggtacatggagt and RhoA-R-gtgcagaggagggctgttag respectively, with carried XhoI and NotI restriction sites in the forward or the reverse position. PCR amplifications from 3’ UTR and the complementary sequences were confirmed by sequencing and cloned into XhoI and NotI sites downstream of Renilla luciferase in the psiCheck2 vector (Promega, Madison, WI). For analysis of luciferase activity, 293A cells were seeded in 12 well plates, transfected 24 hours later with psicheck vectors containing the 3’ UTR or complementary sequences (R) from ETAR, LPAR1 and RhoA genes and miR-200c or miR-control. Luciferase was measured using the Dual Luciferase Kit (Promega, Madison, WI) following manufacturer’s instructions and read in a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA).

**Protein Extraction and Western Blotting**

HTM cells were transfected in triplicates, and after 72 hours washed in PBS and lysated in 1X cold RIPA. Protein concentration was determined using Micro BCA Protein Assay Kit (Pierce, Rockford, IL) and equal loading (30 µg) was run in 10-12% SDS-PAGE and transfer to PVDF membranes. Membranes were incubated overnight at 4°C with antibodies against ETAR (Santa Cruz Biotechnology, Santa Cruz, CA), LPAR1 (Abcam, Cambridge, MA), RhoA (Cell Signaling, Beverly, MA) or tubulin (Santa Cruz Biotechnology). Blots were developed using a chemiluminescence detection system (ECL-Plus from Amersham, Buckinghamshire, UK).

**Contractility Assay and Treatments**

Collagen gels were prepared in 24 well plates from rat tail collagen type 1 (1.5 mg/ml, BD Biosciences, Bedford, MA) following manufacturer’s instructions. After 24 hours transfected HTM cells were embedded in the collagen preparation before pouring, and polymerized at 37°C, 5% CO2 for 30 minutes. After polymerization complete media was added and gels were incubated for 48 hours before any treatment. Cells were changed to serum free media for an overnight culture and TGFβ2 (10 ng/ml), LPA (10 µM), ET-1 (200 pM) and, thrombin (1 U/ml) (all from Sigma Aldrich, St. Louis, MO) were added the next morning to serum free media. After 30 minute treatments the gels were detached from the walls and photographed 24 hours later. The gel area was calculated using ImageJ software [47] and transformed from arbitrary units to mm². To evaluate the effects of miR200c on the levels of contraction induced by TGFβ2, LPA, ET-1, thrombin, or serum, the increase in contraction induced by each of these factors in both, cells transfected with miR-200c and cells transfected with scrambled control, was calculated as the difference in gel area between treated and non-treated cells.

---

**Figure 1. LPAR1, ETAR and RhoA are new targets of miR-200c.** (A) Predicted interactions between the seed region of miR-200c and the 3’UTRs from LPAR1, ETAR and RhoA. (B) Percentage of luciferase activity in 293 cells co-transfected with psicheck vectors containing the 3’UTR or complementary sequences (R) from ETAR, LPAR1 and RhoA genes and miR-200c or miR-control. (C) Effect of miR-200c on ETAR, LPAR1 and RhoA at protein level, analyzed in HTM cell cultures by Western blot. (D) Average densitometry of proteins normalized against tubulin. Bars represent standard deviation in three different experiments. Asterisks (*) and (**) represent significant at p<0.05 and 0.01 respectively.

doi:10.1371/journal.pone.0051688.g001
basal level of contraction for each cell line in these experiments was calculated as the difference between miR-control and miR-200c (control - miR200c) in serum free media without any treatment.

Cell Traction Force Microscopy

A solution of acrylamide (8%) and Bis-acrylamide (0.04%), was prepared with 10 mM HEPES. It was mixed with green fluorescent beads (0.2 μm) (Invitrogen) and gelled with 0.5% ammonium persulfate and 0.05% TEMED on a cover slide. The Young modulus of the gels, 17 kN/m², was determined on a cover slide. The Young modulus of the gels, 17 kN/m², was determined based on Zachary, 2006 [48]. The polyacrylamide gel was coated with collagen type 1 (BD Bioscience, Bedford, MA), sterilized with UV and incubated with media for 4 hours. Transfected cells were sparsely seeded on collagen and incubated at 37°C with 5% CO₂, for 48 to 72 hours prior to Cell Traction Force Microscopy (CTFM). CTFM was performed under an inverted microscope (Zeiss X-cite series 120) using a method described in previous studies [49–51]. Briefly, images of cells and fluorescent beads were recorded both before and after cell trypsinization. The trypsinization-induced displacement of fluorescent beads in the gel was mapped, by using a gradient-based digital image correlation technique [52]. The displacement map was converted to the stress distribution, using a numerical algorithm based on the integral Boussinesq solution to generate high-resolution and applying a gradient-based digital image correlation method to track bead displacement after cell trypsinization.

Construction of Recombinant Adenovirus

To inhibit the activity of miR-200c a sponge was used, a miRNA sponge has complementary binding sites to a miRNA of interest that can sequester miRNAs from their endogenous targets and thus serve as a decoy [53]. Replication deficient adenoviruses for miR-200c sponge and null virus were prepared using the Getaway System from Invitrogen, following manufacturing’s instructions. Briefly, miR-200c sponge was obtained through amplifying the 3'UTR from the ZEB1 gene that contain two target sites for miR-200c, using the following primers: F- ggtacgcatctacctgagctgtagtttgaagacatacag and R-cctcgagattaatactgccaggtttaggtgaagacatacag. The PCR product (197 bp) was cloned in 2.1 TOPO vector (Invitrogen) and confirmed by sequencing. The 3'UTR region was release from digestion with BamHI and XhoI restriction enzymes and introduced into pENTR1A (Invitrogen). MiR-200c 3'UTR/pentr1A plasmid was recombined with pAD/CMV/V5-DEST (Invitrogen) using LR recombinase (Invitrogen) and sequencing to confirm it. pAD-CMV-miR200c-sponge was transfected to 293A cells using lipofectamine 2000. Null virus was prepared by transfecting 293 with pAD-CMV/V5-DEST. Viruses were purified and titer determined using the Adenovirus mini purification Kit (VIRAPUR, San Diego, CA) and Adeno-X Rapid Titer Kit (Clontech, Mountain View, CA) respectively.

In Vivo Injections and IOP Measurements

Sprague-dawley male rats, 6–7 weeks old (Harlan Laboratories), were anesthetized intraperitoneally with a mixture of ketamine-xylazine (60 mg/Kg ketamine and 5 mg/Kg xylazine) plus topic anesthetic before intraocular injections in both eyes, one with
control and the other with experimental treatment, using Hamilton syringes (33 gauges). Seven rats were injected with miR-200c mimic and scramble mimic (Dharmacon, 6 ug/10 ul) using The Max Suppressor In Vivo RNA-LANCER II (Bioo Scientific, Austin, TX) following manufacturer's instructions; rats were injected twice, at days 2 and 6. Eight rats were injected with adenovirus expressing miR-200c inhibitor (miR-200c sponge, $1 \times 10^{9}$ pfu, 10 µl) and with null adenovirus (empty virus, $1 \times 10^{9}$ pfu, 10 µl). IOP was measured in the dark phase, every day, in animals anesthetized with inhaled isoflurane (Butler Animal Health Supply, Dublin, OH), using a portable tonometer (Tonolab, Helsinky, Finland). Relative changes in IOP were calculated as a percentage of the eye injected with experimental treatment compared to the contra lateral eye injected with control.

Statistical Analysis

The data were presented as the mean ± SD. The significance of the data was analyzed using non-paired Student’s t-test for experiments conducted with cells, and paired Student’s t-test for the analysis of IOP in animals. A probability of less than 5% was considered statistically significant.

Results

miR-200c Down-regulates Genes Involved in Cell Contraction

Gene expression profile was analyzed by gene arrays in HTM cells transfected with miR-200c or scramble control (data not showed); from a list of genes with fold change ≥2.0 or ≤-2.0 and p-value ≤0.05 three genes ETAR, LPAR1 and FHOD1 (Table 2) were selected for further analysis because they were down regulated, predicted targets of miR-200c and affect cell contraction. ETAR is a receptor of Endothelin-1, LPAR1 is a receptor of lisophosphatidic acid and FHOD1 mediates thrombin stress fiber formation. The down-regulation of these genes was confirmed by Q-PCR in two different cell lines (HTM 36 and HTM 88), along with ZEB1 and ZEB2, two established targets of miR-200c and transcriptional repressors of E-cadherin and epithelial to mesenchimal transition [39–41] (Table 2). ETAR and LPAR1 are predicted as targets for miR-200c from three databases: Microcosm (http://www.ebi.ac.uk/enrightsrv/microcosm/htdocs/targets/v5/) TargetScan (http://www.targetscan.org), and PicTar-Vert (http://pictar.mdc-berlin.de/). FHOD 1 was recently described as a miR-200c target [43]. Efficiency of transfection of mirnas in HTM cells was evaluated by the reduction of miR-200c established targets (Table 2) and by fluorescent microscopy and fluorescent activated cell sorting (FACSCAN) after transfection with a fluorescent mirna (Figure S1A, S1B and S1C).
LPAR1, ETAR and RhoA are Direct Targets of miR-200c

MiRNA databases show that miR-200c shares complementarities with sequences in the 3'UTR of ETAR, LPAR1 and FHOD1 and these genes were found to be down-regulated by miR-200c in arrays and Q-PCR analyses. RhoA is another predicted target that, although did not change in our array analyses, it was included in the investigation because of its important role in cell contraction (Figure 1A). The interaction among the 3'UTRs of ETAR, LPAR1 and RhoA with miR-200c was analyzed using the psiCheck2 luciferase assay system. MiR-200c mimic significantly reduced luciferase expression in cells co-transfected with the 3'UTR of ETAR, LPAR1 and RhoA compared to mimic control (scrambled). The decrease in luciferase activity was prevented when the 3'UTR complementary sequences were used (Figure 1B).

Down-regulation of Etar, Lpar1 and RhoA proteins by miR-200c was confirmed by Western blot in HTM cells (Figure 1C and 1D).

MiR-200c Inhibits Contraction of TM cells in Collagen Populated Gels

To evaluate the effects of miR-200c on HTM cell contraction, two primary cell cultures were transfected in triplicates, with control or miR-200c, embedded in collagen gels and the gel area was measured at 24 hours after gel detachment. Cell contraction was assessed in complete media, media without serum and media without serum and ET-1, LPA, thrombin or TGFβ2. These factors were chosen because they are known to induce contraction of trabecular meshwork, and miR-200c targeted main receptors for ET-1 and LPA (ETAR and LPAR1), and a gene inducing stress fiber formation by thrombin activation (FHOD1). Figure 2A showed the difference in contraction between cell transfected with control and miR-200c for each cell line. The difference in contraction induced by serum, ET-1, LPA, thrombin or TGFβ2 is showed in Figures 2A, 2C and 2D. Cells transfected with miR-200c exhibited a significant decrease in contractility in response to serum, LPA, ET-1 and TGFβ2 compared to controls. On average the cells in complete media showed the biggest difference in contraction between miR-200c and scramble (28.8 mm²). In some instances miR-200c abolished almost completely the contractile response to these treatments (Figure 2C and 2D).

MiR-200c Reduces Traction Force in HTM cells after Stimulation with Serum

Cell traction force plays a key role in many physiological and pathological processes through actomyosin interactions. The approach to measure cell traction forces is based on the use of flexible polyacrylamide coated with extracellular matrix protein for cell adhesion and embedded with fluorescent beads for tracking the deformation as a result of exerted forces by individual cells [54]. In order to analyze the effects of miR-200c on the traction force of HTM cells we measured stress distribution using CTFM technique in cells transfected with miR-200c or control with and without serum (Figure 3A). In complete media, cells transfected with miR-200c exhibited less mean traction force than cells with miRNA control; this difference was reduced when cells were kept...
in media without serum. The average difference between mean traction force in cells with and without serum in the control group was statistically significant; but in cells transfected with miR-200c there was no significant difference (Figure 3B and 3C).

**MiR-200c Modulates IOP in vivo**

To investigate if miR-200c could be relevant for regulation of intraocular pressure *in vivo*, rats were injected intracamerally with miR-200c mimic, control mimic, Ad-miR-200c-sponge and Ad-empty virus. The efficacy of miR-200c sponge was confirmed by Q-PCR in HTM cells (Figure S2B). Following injections there was no evidence of inflammation or redness in the eyes. The eyes injected with miR-200c mimic showed a reduction in IOP compared to the contra-lateral eye injected with control mimic, the maximum difference between the two eyes was observed at day 8 with average IOP of 21.2 mmHg in the control and 15.1 mmHg in the experimental. The reduction in IOP was significant during seven days but just after a second injection of miRNA on Day 5, and this reduction effect lasted for 9 days. Eyes injected with Ad-miR200c-sponge showed a significant increase in IOP compared to the contra-lateral eye injected with empty virus. The maximum difference between both eyes was observed at day 6 with average IOP of 14.7 mmHg in the control and 24.2 mmHg in miR-200c sponge, this effect was statistically significant during the 6 days that the effect lasted (Figure 4).

**Discussion**

Our results showed that cells transfected with miR-200c down-regulated ZEB1, ZEB2, FHOD1, LPAR1/EDG2, ETAR; the same treatment also down regulated RhoA at protein level. FHOD1 was recently described as a target of miR-200c; and here we identified ETAR, LPAR1/EDG2, and RhoA as novel targets of miR-200c as well. All these proteins play roles potentially relevant to the regulation of the tone of the TM cells. ZEB1 and ZEB2 regulate the expression of SMA that is known to be induced by TGFβs in HTM cells [55,56]. FHOD1 and RhoA are well known activators of the actomyosin system [57,58]. ETAR is one of two major ET-1 receptors and mediates the increase in intracellular calcium and vasoconstriction induced by ET-1. While the second type of ET-1 receptor, ETBR, frequently counter-regulates ETAR activity through production of nitric oxide and ET-1 clearance, ETAR mediates the ET-1 induced contraction of cells, including TM cells [25,28,35,59-63]. The physiological agonist of LPAR1, LPA, has been demonstrated to increase cell contraction of cells in the outflow pathway [33,34].

Consistent with the observed posttranscriptional inhibition of multiple genes involved in the regulation of the contractile responses, HTM cells transfected with miR-200c showed a decreased response in cell traction forces. Cell traction forces direct many cellular functions, as cell migration, ECM organization, and generation of mechanical signals. Mir-200c reduced contractile forces direct many cellular functions, as cell migration, ECM organization, and generation of mechanical signals. Mir-200c reduced contractile forces of cells and in some cases almost abolished the contractile responses induced by ET-1, LPA, and TGFβ2. In HTM cells LPA, TGFβ2 and RhoA have been shown to induce alpha-SMA [55] and ET-1 increased alpha-SMA in pulmonary fibroblast [64]. Alpha-SMA has been shown to up-regulate cell traction force in myofibroblasts in a direct fashion [65,66]. Furthermore, transfection of HTM cells with miR-200c significantly decreased traction forces in single cells in presence of serum. Serum contains a complex mixture with growth factors, cytokines, and enzymes, and is known to induce cell contraction in several cell types [67-69]. Serum includes multiple factors present in the aqueous humor that can induce trabecular contraction such as ET-1, LPA and TGFβ2 [24–32].

ET-1, LPA and TGFβ2 have been implicated in pathogenic increase in tissue stiffness and aqueous outflow resistance observed in glaucomatous TM [70]. These factors present in the aqueous humor have been proven to exert significant effects on outflow facility. ET-1 has been related to alterations in IOP, ocular blood flow, optic nerve integrity and retinal ganglion cell survival [53]. Increased presence of ET-1 in the AH is believed to contribute to the pathogenesis of the outflow pathway in eyes with POAG [28,60,61,63] and inhibition of ET-1 signaling is considered to be one of the new potential approaches to the treatment of glaucoma [62,71]. The potential role of ET-1 in glaucoma might result from two different mechanisms: (1) increased vasoconstriction causing a decrease in ocular supply to the retina and the optic nerve head, and (2) IOP elevation as a result of an increase in TM cell contraction [63]. In addition, ET-1 is believed to exert pathogenic effects by inducing the production of reactive oxygen species through an ETAR dependent mechanism [59]. LPA and thrombin has been shown to reduce outflow facility in a porcine ex-vivo model and to increase stress fiber formation and MLC phosphorylation in Schlemm’s canal cells [33].

The potential role of LPAR1 in outflow pathway is particularly interesting in light of the recent observation that autotaxin, an enzyme that generates LPA, is elevated in AH from POAG donors, and its inhibition decreases significantly the IOP in rabbits [72]. Finally, TGFβ2 have been found to be elevated in the aqueous humor of glaucomatous eyes compared to age matched controls [73]; TGFβ2 can stimulate secretion of extracellular matrix factors [74,75], induce cross linking actin networks (CLAN) formation in TM cells [76] and induce endothelin-1 synthesis in HTM [36]. In addition, expression of a constitutively active form of TGFβ2 in the TM of mice and rats is known to elevate IOP and reduce outflow facility [77].

The observed effects of miR-200c on the responses induced by ET-1, LPA and TGFβ2 suggest that miR-200c might exert important effects on IOP. MiR-200c injected into the anterior chamber of rat eyes caused a significant decrease on IOP. This effect was accumulative since it was higher after two injections of miR-200c mimic. It also appeared to last longer than the short life of miR-mimics, suggesting that some of the changes induced by the increased miR-200c expression might persist for some time after miR-200c has returned to basal levels. The eyes injected with either miR-200c mimic or control showed a larger level of IOP fluctuations than those treated with adenoviral vectors, suggesting that the method of delivery could potentially influence IOP stability. Testing and optimizing more effective methods for delivery of miRNAs to the cells of the outflow pathway will be an important objective for future studies aimed at analyzing the functional effects of miRNAs in the outflow pathway and evaluate their therapeutic potential as IOP lowering agents. The effects of miR-200c on IOP were further supported by the increase in IOP observed after inhibition of miR-200c using an adenoviral vector expressing a molecular sponge. Surprisingly, the IOP returned to normal values only 6 days after viral delivery. This decrease in IOP appeared to occur too early to be attributable to silencing of the CMV promoter activity which has been reported to occur at least a few weeks after viral delivery in multiple organs [78].

Therefore, other unidentified mechanisms may be responsible for the observed recovery in IOP. Similarly, it is worth mentioning that microRNAs are known to have multiple targets, and it is likely that additional miR-200c targets might be involved in the observed effects of this miRNA on outflow facility. Further studies
will be needed to fully understand the mechanism behind the effects of miR-200c in vivo.

In conclusion, our results demonstrate for the first time the ability of a miRNA to regulate trabecular contraction and modulate IOP in vivo, making miR-200c worthwhile candidate for exploring ways to alter trabecular contractility with therapeutic purposes in glaucoma.

Supporting Information

Figure S1 HTM transfection Efficiency. HTM cells were transfected using lipofectamine with a fluorescent miRNA (DY547) and analyzed 48 hours after transfection. Panel A. Light microscopy image of HTM cells. Panel B. Fluorescent image of the same field, red is fluorescent miRNA, and blue are nuclei counterstained with DAPI (1 mg/ml) (original magnification ×100). Panel C. Fluorescent activated cell sorting (FACS) analysis of HTM cells transfected with fluorescent miRNA. (TIF)

References

1. Marpea O, Bill A (1992) Pressures in the juxtapapillary tissue and Schlemm’s canal in monkeys. Exp Eye Res 54: 879–883.
2. Moses KA (1977) The effect of intraocular pressure on resistance to outflow. Surv Ophthalmol 22: 80–100.
3. Arend KD, Roffbrake C (2005) Update on prospective glaucoma intervention studies. Klin Monbl Augenheilkd 222: 807–813.
4. Chang EE, Goldberg JL (2012) Glaucoma 2.0: neuroprotection, neuroregeneration, neuroremodulation. Ophthalmology 119: 979–980.
5. Ansari K, Wimreb R (2012) Continuous 24-hour intraocular pressure monitoring for glaucoma-tome a paradigm change. Swiss Med Wkly 142: w13545.
6. Tan JC, Peters DM, Kaufman PL (2006) Recent developments in understanding the pathophisiology of elevated intraocular pressure. Curr Opin Ophthalmol 17: 108–174.
7. Tamam ER (2009) The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res 88: 648–655.
8. Tamam ER, Fuchshofer R (2007) What increases outflow resistance in primary open-angle glaucoma? Surv Ophthalmol 52 Suppl 2: S101–S104.
9. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, et al. (2008) Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 126: 369–375.
10. Rao VP, Epstein DL (2007) Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 21: 167–177.
11. Tian B, Gabelt BT, Geiger B, Kaufman PL (2009) The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res 89: 713–717.
12. Epstein DL, Roche LL, Roberts RC (1999) Actomyosin drug effects and aqueous outflow function. Invest Ophthalmol Vis Sci 40: 74–81.
13. Wierderholt M, Sturm A, Lepple-Wienhues A (1994) Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci 35: 2515–2520.
14. Wierderholt M, Groth J, Strauss O (1998) Role of protein tyrosine kinase on regulation of trabecular meshwork and ciliary muscle contractility. Invest Ophthalmol Vis Sci 39: 1012–1020.
15. Krauss AH, Wiedenholt M, Sturm A, Woodward DF (1997) Prostaglandin F2alpha effects on the contractility of bovine trabecular meshwork and ciliary muscle. Exp Eye Res 64: 447–453.
16. Rao PV, Deng PF, Kumar J, Epstein DL (2001) Modulation of aqueous humor outflow facility by the rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 42: 1029–1037.
17. Wierderholt M, Schafer R, Wagner U, Lepple-Wienhues A (1996) Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol 5: 146–153.
18. Zhang M, Rao PV (2005) Beblastatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes. Invest Ophthalmol Vis Sci 46: 4130–4133.
19. Thieme H, Nukrovi K, Nasr JU, Pleyer U, Strauss O, et al. (2006) Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A. Invest Ophthalmol Vis Sci 41: 4240–4246.
20. Rao PV, Deng P, Sasaki Y, Epstein DL (2005) Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humor outflow facility. Exp Eye Res 80: 197–206.
21. Syriani C, Eusto C, Ahad E, Pelaez T, Gual A, et al. (2009) Effects of platelet-derived growth factor on aqueous humor dynamics. Invest Ophthalmol Vis Sci 50: 3833–3839.
22. Tian B, Kaufman PL (2005) Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. Exp Eye Res 80: 215–225.
23. Yu M, Chen X, Wang N, Cai S, Li N, et al. (2008) H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes. J Oral Pharmacol Ther 24: 373–379.
24. Cousins SW, McCabe MM, Danielpour D, Stelecin JW (1991) Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 32: 2201–2211.
25. Gnece M, Vural H, Satici A (2001) Endothelin-1 increases in aqueous humour caused by frequency-doubled Nd:YAG laser trabeculoplasty in rabbits. Eye (Lond) 15: 781–783.
26. Hayasaka K, Okawa S, Hashizume E, Kostke H, Midorikawa H, et al. (1998) Anti-apoptotic effect of TGFBeta in aqueous humor. Life Sci 63: 1099–1096.
27. Iswabe S, Lamas M, Vasquez Palcez CG, Carrasco PG (2010) Aqueous humour endothelins-1 (E-1), vascular endothelial growth factor (VEGF) and cytochrome-oxigenase-2 (COX-2) levels in Mexican glaucomatous patients. Curr Eye Res 35: 287–294.
28. Kalberg ME, Brooks DE, Garcia-Sanchez GA, Komaromy AM, Szabo NJ, et al. (2002) Endothelin 1 levels in the aqueous humor of dogs with glaucoma. J Glaucoma 11: 105–109.
29. Lilom K, Guan Z, Tseng J-L, Doiderer DM, Tiggy G, et al. (1998) Growth factor-like phosphatidylsphingosin formed after corneal injury. Am J Pathol 124: C1065–1074.
30. Tokumura A, Taiza S, Kikuchi M, Tsutsumi T, Shimizu Y, et al. (2012) Lysophosphatidylsphingosin and lysophosphatidic acid as inhibitors of aqueous outflow facility. Invest Ophthalmol Vis Sci 53: 4160–4167.
31. Mettu PS, Deng PF, Miura UK, Gavoith G, Epstein DL, et al. (2004) Role of lysophosphatidyl growth factors in the modulation of aqueous humor outflow facility. Invest Ophthalmol Vis Sci 45: 2263–2271.
32. Shoshani YZ, Harris A, Shoa MM, Rusda D, Siesky B, et al. (2012) Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. Curr Eye Res 37: 31–41.
33. Kumar J, Epstein DL (2011) Rho GTPase-mediated cytoskeletal organization in Schlemm’s canal cells play a critical role in the regulation of aqueous humor outflow facility. J Cell Biochem 112: 600–606.
34. Mettu PS, Deng PF, Miura UK, Gavoith G, Epstein DL, et al. (2004) Role of lysophosphatidyl growth factors in the modulation of aqueous humor outflow facility. Invest Ophthalmol Vis Sci 45: 2263–2271.
35. Shoshani YZ, Harris A, Shoa MM, Rusda D, Siesky B, et al. (2012) Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. Curr Eye Res 37: 31–41.
36. Von Zee CL, Langert KA, Stobbs EB Jr (2012) Transforming Growth Factor-beta2 Induces Synthesis and Secretion of Endothelin-1 in Human Trabecular Meshwork Cells. Invest Ophthalmol Vis Sci.
37. Holley CL, Topkara VK (2011) An introduction to small non-coding RNAs: miRNA and snoRNA. Cardiovasc Drugs Ther 25: 151–159.
38. Stefani G, Shack FJ (2006) Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 9: 219–230.
39. Burk U, Schubert JW, Wellner U, Schmalhofer O, Vincan E, et al. (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9: 582–589.
40. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593–601.
59. Dai ZK, Hsieh CC, Chai CY, Wu JR, Jeng AY, et al. (2010) Protective effects of
58. Takeya R, Taniguchi K, Narumiya S, Sumimoto H (2008) The mammalian
57. Gasteier JE, Madrid R, Krautkramer E, Schroder S, Muranyi W, et al. (2003)
56. Tamm ER, Siegner A, Baur A, Lutjen-Drecoll E (1996) Transforming growth
52. Huang J, Zhu T, Pan X, Qin L, Peng X, et al. (2010) A high-efficiency digital
51. Huang J, Peng X, Qin L, Zhu T, Xiong C, et al. (2009) Determination of
49. Huang J, Deng H, Peng X, Li S, Xiong C, et al. (2012) Cellular traction force
46. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for
45. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW (1995) Isolation
43. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, et al. (2012)
42. Rosenthal R, Fromm M (2011) Endothelin antagonism as an active principle for
glaucoma therapy. Br J Pharmacol 162: 806–816.
40. Yorio T, Krishnamoorthy R, Prasanna G (2002) Endothelin: is it a contributor
to glaucoma pathophysiology? J Glaucoma 11: 259–270.
39. Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, et al. (1999) Effect of
endothelin-1 on alpha-smooth muscle actin expression and on alveolar
fibroblasts proliferation in intestinal lung diseases. Int J Immunopharmacol
21: 759–775.
38. Chen J, Li H, SundarRaj N, Wang JH (2007) Alpha-smooth muscle actin expression
enhances cell traction force. Cell Motil Cytoskeleton 64: 248–257.
37. Hinz B, Celetta G, Tomaesec JJ, Galbmann G, Chaponnier C (2001) Alpha-
smooth muscle actin expression upregulates fibroblast contractile activity.
Mol Cell Biol 12: 2730–2741.
36. Nohe H, Nobe K, Fazal F, De Lanerolle P, Paul RJ (2003) Rho kinase mediates
serum-induced contraction in fibroblast fibres independent of myosin LC20
phosphorylation. Am J Physiol Cell Physiol 284: C599–606.
35. Hunt RC, Pakaunis VA, Choudhury P, Black EP (1994) Cytokines and serum
cause alpha 2 beta 1 integrin-mediated contraction of collagen gels by cultured
retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 35: 941–949.
34. Sethi A, Mao W, Worden RJ, Clark AF (2011) Transforming growth factor-
beta induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes
in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 52: 2147–2152.
33. Wierzbowska J, Robaszkiewicz J, Figszka M, Stankiewicz A (2010) Future
possibilities in glaucoma therapy. Med Sci Monit 16: RA252–259.
32. Iyer P, Lalane R, Challa P, Morris C, Rao V (2011) Autotaxin-LPA Signaling
Axis is a Novel Molecular Target for Lowering Intracocular Pressure in Rabbit
Model ARVO Meeting Abstracts April 22, 2011, Ft, Lauderdale, Fl, USA: 52:
2070.
31. Trivedi RH, Nautatis M, Vroman D, Crosson CE (2011) Influence of race and
age on aqueous humor levels of transforming growth factor-beta 2 in
glaucomatous and nonglaucomatous eyes. J Ocul Pharmacol Ther 27: 477–480.
30. Bollinger KE, Crabb JS, Yuan X, Pediwala T, Clark AF, et al. (2011) Quantitative
proteomics: TGFbeta signaling in trabecular meshwork cells. Invest
Ophthalmol Vis Sci 52: 8287–8294.
29. Sethi A, Mao W, Worden RJ, Clark AF (2011) Transforming growth factor-
beta induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes
in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 52: 5240–5250.
28. O’Reilly S, Pollock N, Currie L, Paraoan L, Clark AF, et al. (2011) Inducers of
cross-linked actin network in trabecular meshwork cells. Invest Ophthalmol
Vis Sci 52: 8287–8294.
27. Bhat N, Wang X, Hou J, Chuang S, Maxfield FR (2011) Endothelin-1 on the alpha-
smooth muscle actin expression and on alveolar fibroblasts proliferation in intestinal
lung diseases. Int J Immunopharmacol 21: 759–775.
26. Noske W, Hensen J, Wiederhold M (1997) Endothelin-like immunoreactivity in
aqueous humor of patients with primary open-angle glaucoma and cataract.
Graefe’s Arch Clin Exp Ophthalmol 235: 531–532.
25. Rosenthal R, Fromm M (2011) Endothelin antagonism as an active principle for
glaucoma therapy. Br J Pharmacol 162: 806–816.
24. Yorio T, Krishnamoorthy R, Prasanna G (2002) Endothelin: is it a contributor
to glaucoma pathophysiology? J Glaucoma 11: 259–270.
23. Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, et al. (1999) Effect of
endothelin-1 on alpha-smooth muscle actin expression and on alveolar
fibroblasts proliferation in intestinal lung diseases. Int J Immunopharmacol
21: 759–775.